Erbin Dai Source Confirmed

OverviewAI-generated summary

Erbin Dai's research focuses on the development of novel therapeutic agents and biomaterials, particularly in the areas of anticoagulation and anti-thrombotic therapies. His work has involved the synthesis and evaluation of glycomimetics, glycopeptides, and sulfated polysaccharides as potential treatments for thrombotic conditions. For instance, he has investigated a PSGL-1 glycomimetic designed to reduce thrombus burden and explored the potential of rechargeable anti-thrombotic coatings for blood-contacting medical devices.

Further research has explored the design of modified heparin molecules with enhanced resistance to enzymatic degradation, aiming to improve their therapeutic efficacy. Dai's group has also examined the relationship between the gut microbiome and drug-induced liver injury, as well as the protective effects of certain compounds on radiation-induced lung injury through immune modulation. His research includes the challenges and solutions in measuring drug-induced liver injury biomarkers using liver-on-a-chip platforms.

Dai is a highly cited researcher with a publication record of 76 articles and an h-index of 26. He has collaborated with researchers at the National Center for Toxicological Research, including Tucker A. Patterson, James M. Oliphant, Katy S Papineau, and Lijun Ren. He leads a research group investigating these scientific areas.

Metrics

• h-index: 26
• Publications: 76
• Citations: 1,741